Brian Buntz

February 22, 2016

1 Min Read
8. Not Hot: Renal Denervation

8. Not Hot: Renal Denervation

After the technology had developed the reputation for being the next-big-thing in medtech--or, at least, one of the most promising technologies in the medical device industry--renal denervation is all but forgotten now after Medtronic released the disappointing clinical trial results in 2014 that found, essentially, that the technology was safe but possibly not effective at reducing treatment-resistant hypertension. The Symplicity HTN-3 study involved a randomized 535 treatment-resistant hypertension patients in 87 U.S. medical centers. After Medtronic announced the disappointing results for its Symplicity trial, Covidien (then a separate company) also announced it would exit its OneShot renal denervation program, which involved technology Covidien acquired through its April 2012 acquisition of Maya Medical.

Continue >>

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like